Drug Profile
Pimobendan
Alternative Names: Acardi; UDCG 115; UDCG 115A; UDCG 115BSLatest Information Update: 07 Sep 2009
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim Pharma KG
- Developer Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- Class Cardiotonics; Pyridazines; Small molecules
- Mechanism of Action Phosphoric diester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Heart failure
- Discontinued Ischaemic heart disorders
Most Recent Events
- 07 Sep 2009 Discontinued for Heart failure in Australia (PO)
- 07 Sep 2009 Discontinued for Heart failure in European Union (PO)
- 07 Sep 2009 Discontinued for Heart failure in USA (PO)